Lv1
30 积分 2024-07-05 加入
Real-world clinical experience with osimertinib in advanced EGFR-mutated non-small cell lung cancer
10小时前
待确认
Response to lorlatinib rechallenge in a case of ALK-rearranged metastatic NSCLC with a resistance mutation to second generation TKIs
1个月前
已完结
Association between programmed death-ligand 1 expression, immune microenvironments, and clinical outcomes in epidermal growth factor receptor mutant lung adenocarcinoma patients treated with tyrosine kinase inhibitors
3个月前
已完结
Association of PD-L1 expression with efficacy of alectinib in advanced NSCLC patients with ALK fusion
3个月前
已完结
Association of RNF43 Genetic Alterations With BRAFV600E and MSIhigh in Colorectal Cancer
3个月前
已完结
Surgically resectable nonsmall cell lung cancer: a contemporary approach
3个月前
已完结
Rapid Advances in Resectable Non-Small Cell Lung Cancer: A Narrative Review
3个月前
已完结
Central Nervous System Efficacy of Furmonertinib (AST2818) Versus Gefitinib as First-Line Treatment for EGFR-Mutated NSCLC: Results From the FURLONG Study
4个月前
已完结
Safety, Clinical Activity, and Pharmacokinetics of Alflutinib (AST2818) in Patients With Advanced NSCLC With EGFR T790M Mutation
4个月前
已完结
Furmonertinib: First Approval
4个月前
已完结
皖公网安备34019202002308
